Trial · NCT00496834

LAAS (Losartan Anti-Atherosclerosis Study)(0954-330)(COMPLETED)

NCT00496834, Phase 4, Completed, Organon and Co; results first posted 2010-12-15

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. LAAS (Losartan Anti-Atherosclerosis Study)(0954-330)(COMPLETED). Trials, record NCT00496834. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00496834

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: LAAS (Losartan Anti-Atherosclerosis Study)(0954-330)(COMPLETED)
NCT number: NCT00496834
Status: Completed
Phases: Phase 4
Enrollment: 201 participants, actual
Lead sponsor: Organon and Co
Conditions: Hypertension
Interventions: losartan potassium, Comparator: carvedilol, Comparator: losartan (+) hydrochlorothiazide (HCTZ), Comparator: carvedilol (+) hydrochlorothiazide
First posted: 2007-07-04
Last updated: 2024-05-22
Results first posted: 2010-12-15

Source ClinicalTrials.gov

Registered outcomes4

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Pulse Wave Velocity (PWV) Changes From Baseline (Visit 2) to 24 Weeks (Visit 6) After the Administration of the Study Drug	Baseline and 24 Weeks	Analysis was performed in the modified intention to treat (mITT) population.
Primary	PWV Changes From Baseline (Visit 2) to 24 Weeks (Visit 6) After the Administration of the Study Drug	Baseline and 24 Weeks	Analysis was performed in the per protocol (PP) population which additionally excludes certain protocol violations as described in the analysis plan.
Secondary	Systolic Blood Pressure (SBP) Mean Changes From Baseline (Visit 2) to 24 Weeks (Visit 6) After the Administration of the Study Drug	Baseline and 24 weeks
Secondary	Diastolic Blood Pressure (DBP) Mean Changes From Baseline (Visit 2) to 24 Weeks (Visit 6) After the Administration of the Study Drug	Baseline and 24 weeks

Source ClinicalTrials.gov

Outcomes4

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	Pulse Wave Velocity (PWV) Changes From Baseline (Visit 2) to 24 Weeks (Visit 6) After the Administration of the Study Drug	Baseline and 24 Weeks	Participants for analysis was modified intention to treat (Number of patients: Losartan group was 88, Carvedilol group was 94). Missing data were imputed by the last observation carried forward (LOCF) technique.	meters/second	MEAN
PRIMARY	PWV Changes From Baseline (Visit 2) to 24 Weeks (Visit 6) After the Administration of the Study Drug	Baseline and 24 Weeks	Participants for analysis was per protocol (Number of patients: Losartan group was 54, Carvedilol group was 67). Missing data were imputed by the last observation carried forward (LOCF) technique. For the primary efficacy endpoints, Per protocol analysis approach was supplementary used.	meters/second	MEAN
SECONDARY	Systolic Blood Pressure (SBP) Mean Changes From Baseline (Visit 2) to 24 Weeks (Visit 6) After the Administration of the Study Drug	Baseline and 24 weeks	Participants for analysis was modified intention to treat (Number of patients: Losartan group was 88, Carvedilol group was 94) Missing data were imputed by the last observation carried forward (LOCF) technique.	mm Hg	MEAN
SECONDARY	Diastolic Blood Pressure (DBP) Mean Changes From Baseline (Visit 2) to 24 Weeks (Visit 6) After the Administration of the Study Drug	Baseline and 24 weeks	Participants for analysis was modified intention to treat (Number of patients: Losartan group was 88, Carvedilol group was 94) Missing data were imputed by the last observation carried forward (LOCF) technique.	mm Hg	MEAN

Source ClinicalTrials.gov

Results by group8

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Value	Spread	Units
Pulse Wave Velocity (PWV) Changes From Baseline (Visit 2) to 24 Weeks (Visit 6) After the Administration of the Study Drug	Losartan	0.28	Standard Deviation 1.29	meters/second
Pulse Wave Velocity (PWV) Changes From Baseline (Visit 2) to 24 Weeks (Visit 6) After the Administration of the Study Drug	Carvedilol	-0.12	Standard Deviation 1.55	meters/second
PWV Changes From Baseline (Visit 2) to 24 Weeks (Visit 6) After the Administration of the Study Drug	Losartan	0.16	Standard Deviation 1.25	meters/second
PWV Changes From Baseline (Visit 2) to 24 Weeks (Visit 6) After the Administration of the Study Drug	Carvedilol	-0.20	Standard Deviation 1.50	meters/second
Systolic Blood Pressure (SBP) Mean Changes From Baseline (Visit 2) to 24 Weeks (Visit 6) After the Administration of the Study Drug	Losartan	-15.08	Standard Deviation 14.59	mm Hg
Systolic Blood Pressure (SBP) Mean Changes From Baseline (Visit 2) to 24 Weeks (Visit 6) After the Administration of the Study Drug	Carvedilol	-14.81	Standard Deviation 15.38	mm Hg
Diastolic Blood Pressure (DBP) Mean Changes From Baseline (Visit 2) to 24 Weeks (Visit 6) After the Administration of the Study Drug	Losartan	-8.43	Standard Deviation 9.29	mm Hg
Diastolic Blood Pressure (DBP) Mean Changes From Baseline (Visit 2) to 24 Weeks (Visit 6) After the Administration of the Study Drug	Carvedilol	-7.81	Standard Deviation 9.61	mm Hg

Source ClinicalTrials.gov

Participant flow6

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	Losartan	101
Overall Study	STARTED	Carvedilol	100
Overall Study	COMPLETED	Losartan	83
Overall Study	COMPLETED	Carvedilol	87
Overall Study	NOT COMPLETED	Losartan	18
Overall Study	NOT COMPLETED	Carvedilol	13

Source ClinicalTrials.gov

Adverse events152

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk	Events
other	Headache	Nervous system disorders	Losartan	8	101	8
other	Headache	Nervous system disorders	Carvedilol	9	100	12
other	Dizziness	Nervous system disorders	Losartan	5	101	5
other	Dizziness	Nervous system disorders	Carvedilol	3	100	3
other	Dizziness postural	Nervous system disorders	Losartan	0	101	0
other	Dizziness postural	Nervous system disorders	Carvedilol	2	100	2
other	Cerebral infarction	Nervous system disorders	Losartan	1	101	1
other	Cerebral infarction	Nervous system disorders	Carvedilol	0	100	0
other	Hypoaesthesia	Nervous system disorders	Losartan	0	101	0
other	Hypoaesthesia	Nervous system disorders	Carvedilol	1	100	1

1 to 10 of 152Source ClinicalTrials.gov

See all 152 adverse events

Adverse event totals6

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	Losartan
Total, all-cause mortality	Carvedilol
Total, other adverse events	Losartan	35	101
Total, other adverse events	Carvedilol	51	100
Total, serious adverse events	Losartan	5	101
Total, serious adverse events	Carvedilol	6	100

Source ClinicalTrials.gov

Papers0

The papers the trial lists on ClinicalTrials.gov.

None in this release.

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons1

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

Comparison
Losartan vs Carvedilol: serious adverse events

Source Trial comparisons

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT00496834

GET https://conductscience.org/api/trials/v1/NCT00496834/events?page=2

API reference For AI assistants